Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acute Sympathetic Blockade and Endogenous Glucose Production
NCT03028571Phase 1Withdrawn
- Sponsor
- Vanderbilt University Medical Center
- Start
- Apr 2017
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of trimethaphan in insulin resistance (IR) (2 arms), sponsored by Vanderbilt University Medical Center. Primary endpoint: Endogenous Glucose Production at 4 hours. Planned start Apr 2017; status: withdrawn.
02
Drugs
trimethaphan
03
Conditions
insulin resistance (IR)
Beyond the preview
Go deeper on NCT03028571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03028571.